BridgeBio (BBIO) reports positive Phase 3 topline Encaleret results

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. reported that it issued a press release titled “BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1.” The disclosure was made in connection with a current report and the press release is attached as Exhibit 99.1.

The company’s common stock trades on the Nasdaq Global Select Market under the symbol BBIO. The report is dated October 29, 2025 and was signed by the President and Chief Financial Officer. Investors can refer to Exhibit 99.1 for the full press release text.

Insights

Biotech clinical disclosures analyst

Company announced positive Phase 3 topline results via press release.

BridgeBio disclosed that it issued a press release reporting positive Phase 3 topline results for Encaleret in autosomal dominant hypocalcemia type 1 (ADH1). The announcement is furnished as Exhibit 99.1, which typically contains the clinical detail supporting the topline statement.

This type of 8‑K signals a potentially meaningful clinical milestone but does not include efficacy or safety metrics in the excerpt. The market relevance depends on the specifics within Exhibit 99.1 and subsequent regulatory or development steps.

The filing is dated October 29, 2025. Further implications, if any, would come from the detailed outcomes and next steps described in the attached press release.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did BridgeBio (BBIO) announce in this report?

BridgeBio stated it issued a press release reporting positive Phase 3 topline results for Encaleret in autosomal dominant hypocalcemia type 1.

When is the report dated for BridgeBio (BBIO)?

The report is dated October 29, 2025.

Where can I find the full BridgeBio press release?

The press release is attached as Exhibit 99.1 to the report.

What is BridgeBio’s (BBIO) stock exchange and ticker?

BridgeBio’s common stock trades on the Nasdaq Global Select Market under the symbol BBIO.

What is the subject of the clinical update for BBIO?

The update concerns positive Phase 3 topline results for Encaleret in patients with autosomal dominant hypocalcemia type 1 (ADH1).

Who signed the BridgeBio report?

The report was signed by Thomas Trimarchi, Ph.D., President and Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/29/2025 - 04:09 PM Learn about SEC filing dates

false000174388100017438812025-10-292025-10-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):October 29, 2025

BridgeBio Pharma, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-38959	84-1850815
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

3160 Porter Dr., Suite 250
Palo Alto, CA		94304
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 391-9740

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	BBIO	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events

On October 29, 2025, BridgeBio Pharma, Inc. issued a press release titled “BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit	Description
99.1	Press Release titled, “BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1”
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			BridgeBio Pharma, Inc.
Date:	October 29, 2025	By:	/s/ Thomas Trimarchi
			Thomas Trimarchi, Ph.D.
			President and Chief Financial Officer